“…Some research opposes the preference for STN over GPI in PD patients, as there is evidence of equivalent improvements in motor symptoms and some potential benefits of GPI-DBS, such as improved dyskinesia control that allows for greater flexibility in dosing parameters without risking medication-induced dyskinesia ( Vitek, 2003 ). In theory, the larger size and lower density of functional circuitry in the GPI may also reduce risk of unintentional current spread to non-target functional circuits ( Zimpel et al, 2023 ). No comparison studies have shown significant differences in stimulation-induced motor side effects between the two targets, although there is evidence that GPI-DBS results in slightly better neurocognitive outcomes ( Combs et al, 2015 , Odekerken et al, 2013 , Okun et al, 2009 ).…”